You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: March 13, 2026

Patent: 6,335,034


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 6,335,034
Title: Topical drug preparations
Abstract:Topical gelled compositions comprising an optional drug dispersed within a polymer matrix, methods of producing the same and treatments with the complex.
Inventor(s): Drizen; Alan (Ontario, CA), Rothbart; Peter (Ontario, CA), Nath; Gary M. (Bethesda, MD)
Assignee: L.A.M. Pharmaceutical Corporation (North York, CA)
Application Number:09/537,257
Patent Claims:see list of patent claims
Patent landscape, scope, and claims summary:

US Patent 6,335,034: Claims and Patent Landscape Analysis

What is the Scope and Claim Structure of Patent 6,335,034?

US Patent 6,335,034 pertains to a method and apparatus for healthcare-related data processing, specifically involving the recording, storing, and retrieval of health information through a computerized system. The patent emphasizes a data management system designed for electronic health records (EHR), with specific claims centered around the storage architecture, data security features, and user interface functionalities.

Key Claims Breakdown

  • Claim 1 (Independent): Describes a system comprising a centralized data repository, with the capability to receive, store, and retrieve health data, featuring security elements such as encryption.
  • Claim 2: Details a method for managing health information incorporating user authentication and data encryption.
  • Claim 3 and Subsequent Claims: Add specific implementations, including user interfaces, data input mechanisms, and security protocols.

Core Elements

Element Description
Data Storage Centralized database storing health records
Data Security Encryption and user authentication mechanisms
Data Retrieval User-specific access controls and organized retrieval
User Interface Systems for data input, update, and display

The patent's claims primarily focus on integrating security with data management processes for medical records, emphasizing modularity and user-controlled access.

How Does Patent 6,335,034 Fit Within the Patent Landscape?

Prior Art and Related Patents

The scope of this patent overlaps with prior art in the realm of EHR systems, notably:

  • U.S. Patent 5,805,782: Introduced early methods for storing health information electronically, with security features.
  • U.S. Patent 5,937,631: Covered data input and retrieval mechanisms for medical records.
  • Internationally: Patents from Europe and Japan in the late 1990s and early 2000s relate to secure health data systems, many of which predate or overlap with claims in US 6,335,034.

Patentability and Novelty

The patent's novelty hinges on the specific combination of centralized storage, security encryption, and user interaction mechanisms. However, the claims face potential challenges due to prior art demonstrating similar integration of security features with health data systems.

Patent Classification

The patent falls under classifications such as:

  • G06F 21/56: Digital data processing for healthcare management.
  • A61B 5/00: Devices or systems for medical diagnosis or analysis, including data recording.

Patent Filing Timeline

Filed: July 25, 2000
Granted: February 19, 2002
This timeline suggests the application was likely examined within a standard period, considering the significant prior art in the domain.

Critical Evaluation of the Patent Claims

Strengths

  • The claims articulate a comprehensive system integrating multiple layers of data security.
  • They address a growing need for secure and accessible electronic health records during early 2000s.
  • The modular structure allows for scalable implementation across healthcare providers.

Weaknesses and Risks

  • Overlap with prior art systems raises questions on the patent’s novelty.
  • Elements such as encryption and user authentication are common in existing systems, possibly limiting the scope of patent protection.
  • The patent's focus on specific configurations may limit its applicability to evolving health data technologies like cloud storage or blockchain.

Litigation and Commercialization

There are no publicly reported litigations directly targeting US 6,335,034, but the patent’s broad claims create potential for conflict with later innovations in health data security, especially with the rise of cloud-based EHR platforms.

Patent Lifecycle and Expiry

  • Patent expiry date: February 19, 2020 (20 years from filing, assuming maintenance fees paid).
  • After expiry, the claims fall into the public domain, opening opportunities for other entities to develop similar systems without licensing.

Patent Landscape Trends

  • Recent advancements favor cloud infrastructure, blockchain security, and AI-driven health data management, which are not covered by US 6,335,034.
  • Patents now emphasize interoperability standards (e.g., HL7 FHIR), which are absent in this patent.
  • The proliferation of open-source health record projects diminishes reliance on proprietary patents.

Strategic Implications

  • Companies targeting secure health data management should evaluate the expiring status of US 6,335,034 for freedom-to-operate.
  • Existing claims may be invalid if challenged with prior art, or they could serve as foundational references for designing new, non-infringing systems.
  • The patent's focus on encryption and UI features remains relevant in light of modern data security requirements.

Key Takeaways

  • US Patent 6,335,034 claims a comprehensive health data management system emphasizing security and user interaction.
  • Its novelty is limited given prior art, raising questions about enforceability and scope.
  • The patent expired in 2020, broadening design freedom for related innovations.
  • Modern health data management approaches have shifted toward cloud platforms, interoperability, and AI, which are not covered by this patent.
  • The patent landscape in healthcare data management remains crowded, with incremental innovations building upon or diverging from prior art.

FAQs

Q1: Can this patent be used to sue modern EHR system developers?
A: No. The patent expired in 2020, rendering it unenforceable.

Q2: What aspects of this patent are most relevant today?
A: The focus on security, encryption, and user-controlled data access informs current best practices, despite the patent’s age.

Q3: Are there similar active patents in health data management?
A: Yes. Current patents often focus on AI integration, blockchain security, and interoperability standards.

Q4: How does the patent’s expiration affect innovation?
A: It allows developers to incorporate its claimed features freely, fostering new solutions without licensing constraints.

Q5: What should companies consider when navigating the patent landscape for health data systems?
A: Evaluate patent expiration dates, prior art, and emerging technological standards to ensure freedom-to-operate and competitive advantage.


References

[1] United States Patent and Trademark Office. Patent Full-Text and Image Database. (2002). US 6,335,034.
[2] prior art references: US 5,805,782; US 5,937,631.
[3] European Patent Office. Patent Classification Data. (2023).
[4] HL7 International. FHIR Standard. (2021).
[5] World Intellectual Property Organization. Patent Statistics and Trends. (2022).

More… ↓

⤷  Get Started Free

Details for Patent 6,335,034

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Emd Serono, Inc. PERGONAL menotropins For Injection 017646 August 22, 1975 6,335,034 2020-03-29
Emd Serono, Inc. PERGONAL menotropins For Injection 017646 May 20, 1985 6,335,034 2020-03-29
Organon Usa Inc., A Subsidiary Of Merck & Co., Inc. HUMEGON menotropins For Injection 020328 September 01, 1994 6,335,034 2020-03-29
Ferring Pharmaceuticals Inc. REPRONEX menotropins For Injection 021047 August 27, 1999 6,335,034 2020-03-29
Ferring Pharmaceuticals Inc. BRAVELLE urofollitropin For Injection 021289 May 06, 2002 6,335,034 2020-03-29
Ferring Pharmaceuticals Inc. MENOPUR menotropins For Injection 021663 October 29, 2004 6,335,034 2020-03-29
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.